Cybin Inc.

Cybin Inc. is a biotechnology company specializing in advancing psychedelic therapeutics. It focuses on developing drug candidates based on psilocybin and other psychoactive compounds for mental health applications. Cybin aims to innovate new formulations and delivery methods to enhance efficacy and safety profiles. The company operates within the rapidly evolving biopharmaceutical sector, targeting neuropsychiatric disorders such as depression, anxiety, and substance use disorders. Cybin’s role in the financial markets represents the growing investor interest in the mental health and psychedelics space, reflecting broader trends in pharmaceutical innovation and alternative medicine research. Its stock is listed on multiple exchanges, including a secondary listing on the Berlin Stock Exchange, which expands its access to European investors and highlights its international presence in capital markets.